{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:47:02Z","timestamp":1791074822547,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.gtc.2006.03.004","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:09:23Z","timestamp":1168441763000},"page":"229-247","source":"Crossref","is-referenced-by-count":62,"title":["Helicobacter pylori Diagnosis and Management"],"prefix":"10.1016","volume":"35","author":[{"given":"Ratha-Korn","family":"Vilaichone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varocha","family":"Mahachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.gtc.2006.03.004_bib1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archinte.157.13.1489","article-title":"Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States","volume":"157","author":"Munnangi","year":"1997","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.gtc.2006.03.004_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/gut.16.8.590","article-title":"Mucosal changes in gastric ulceration and their response to carbenoxolone sodium","volume":"16","author":"Steer","year":"1975","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.1711460409","article-title":"The gastro-duodenal epithelium in peptic ulceration","volume":"146","author":"Steer","year":"1985","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.gtc.2006.03.004_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jcp.28.8.639","article-title":"Ultrastructure of cell migration through the gastric epithelium and its relationship to bacteria","volume":"28","author":"Steer","year":"1975","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gtc.2006.03.004_bib5","series-title":"The immunobiology of H. pylori from pathogenesis to prevention","first-page":"1","article-title":"The epidemiology of H. pylori-associated gastroduodenal diseases","author":"Breuer","year":"1997"},{"issue":"8","key":"10.1016\/j.gtc.2006.03.004_bib6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/BF01297451","article-title":"Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries","volume":"36","author":"Graham","year":"1991","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1086\/315384","article-title":"Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States","volume":"181","author":"Everhart","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/gut.35.6.742","article-title":"Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection","volume":"35","author":"Malaty","year":"1994","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/CDLI.12.1.81-85.2005","article-title":"Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam","volume":"12","author":"Hoang","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib10","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/infdis\/168.6.1549","article-title":"Diagnosis of Helicobacter pylori infection in a developing country: comparison of two ELISAs and a seroprevalence study","volume":"168","author":"Bodhidatta","year":"1993","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4269\/ajtmh.1999.60.587","article-title":"Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico","volume":"60","author":"Leal-Herrera","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib12","first-page":"1313","article-title":"Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and cagA antigens","volume":"9","author":"Romero-Gallo","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1523-5378.1998.08011.x","article-title":"Comparison of Helicobacter pylori infection between Fukuoka, Japan and Chinju, Korea","volume":"3","author":"Youn","year":"1998","journal-title":"Helicobacter"},{"issue":"9","key":"10.1016\/j.gtc.2006.03.004_bib14","article-title":"Intrafamilial transmission of Helicobacter pylori in Thailand","volume":"1006","author":"Mahachai","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ije\/31.3.646","article-title":"What remains to be done regarding transmission of Helicobacter pylori","volume":"31","author":"Graham","year":"2002","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0025-7125(02)00083-4","article-title":"Pathogenesis and therapy of gastric and duodenal ulcer disease","volume":"86","author":"Shiotani","year":"2002","journal-title":"Med Clin North Am"},{"issue":"25","key":"10.1016\/j.gtc.2006.03.004_bib17","doi-asserted-by":"crossref","first-page":"14648","DOI":"10.1073\/pnas.93.25.14648","article-title":"cagA pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors","volume":"93","author":"Censini","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.gtc.2006.03.004_bib18","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1073\/pnas.130079797","article-title":"A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori","volume":"97","author":"Yamaoka","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/00365520510012299","article-title":"Gastric mucosal cytokine levels in relation to host interleukin-1 polymorphisms and Helicobacter pylori cagA genotype","volume":"40","author":"Vilaichone","year":"2005","journal-title":"Scand J Gastroenterol"},{"issue":"7924","key":"10.1016\/j.gtc.2006.03.004_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(75)90498-5","article-title":"A model for gastric cancer epidemiology","volume":"2","author":"Correa","year":"1975","journal-title":"Lancet"},{"issue":"11 Suppl","key":"10.1016\/j.gtc.2006.03.004_bib21","first-page":"2554","article-title":"Precursors of gastric and esophageal cancer","volume":"50","author":"Correa","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.gtc.2006.03.004_bib22","first-page":"301","article-title":"The biological model of gastric carcinogenesis","volume":"157","author":"Correa","year":"2004","journal-title":"IARC Sci Publ"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/gut.2004.056549","article-title":"The time to eradicate gastric cancer is now","volume":"54","author":"Graham","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2006.03.004_bib24","series-title":"Cancer incidence in five continents, vol . VIII","year":"2002"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib25","first-page":"226","article-title":"Gastric pseudolymphoma. A spectrum of presenting features and diagnostic considerations","volume":"65","author":"Perrillo","year":"1976","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2559.1979.tb03012.x","article-title":"Benign and malignant lymphoid lesions of the stomach. A histological reappraisal in the light of the Kiel classification for non-Hodgkin's lymphomas","volume":"3","author":"Vanden Heule","year":"1979","journal-title":"Histopathology"},{"issue":"8776","key":"10.1016\/j.gtc.2006.03.004_bib27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0140-6736(91)92035-Z","article-title":"Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma","volume":"338","author":"Wotherspoon","year":"1991","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.gtc.2006.03.004_bib28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199405053301803","article-title":"Helicobacter pylori infection and gastric lymphoma","volume":"330","author":"Parsonnet","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3748\/wjg.v10.i2.223","article-title":"Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 10 year follow-up","volume":"10","author":"Lee","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002096.pub2","article-title":"Eradication of Helicobacter pylori for non-ulcer dyspepsia","volume":"25","author":"Moayyedi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.gtc.2006.03.004_bib31","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/j.1572-0241.1998.00684.x","article-title":"Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology","volume":"93","author":"Howden","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"7535","key":"10.1016\/j.gtc.2006.03.004_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.38702.662546.55","article-title":"Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter Project: randomized controlled trial","volume":"332","author":"Lane","year":"2006","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.gtc.2006.03.004_bib33","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/j.1572-0241.2003.07533.x","article-title":"The changing epidemiology of GERD: geography and Helicobacter pylori","volume":"98","author":"Graham","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gtc.2006.03.004_bib34","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/archinte.160.9.1349","article-title":"Helicobacter pylori\u2013is it a novel causative agent in vitamin B12 deficiency?","volume":"160","author":"Kaptan","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6 Suppl","key":"10.1016\/j.gtc.2006.03.004_bib35","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/S0016-5085(97)80023-6","article-title":"Can therapy ever be denied for Helicobacter pylori infection?","volume":"113","author":"Graham","year":"1997","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-126-4-199702150-00004","article-title":"Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences","volume":"126","author":"Ofman","year":"1997","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1586\/14787210.2.4.599","article-title":"Helicobacter pylori infection: diagnosis and treatment","volume":"2","author":"Nakayama","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.gtc.2006.03.004_bib38","first-page":"499","article-title":"Markers of infection. Helicobacter pylori: Physiology and genetics","author":"Graham","year":"2001"},{"issue":"9172","key":"10.1016\/j.gtc.2006.03.004_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(98)08103-3","article-title":"Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group","volume":"354","author":"Vaira","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1523-5378.2005.00355.x","article-title":"Methodology and transport medium for collection of Helicobacter pylori on a string test in remote locations","volume":"10","author":"Windsor","year":"2005","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-5378.2005.00285.x","article-title":"Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture","volume":"10","author":"Graham","year":"2005","journal-title":"Helicobacter"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib42","first-page":"288","article-title":"Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains","volume":"11","author":"El-Zimaity","year":"1998","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0016-5107(96)70002-0","article-title":"Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori","volume":"44","author":"Laine","year":"1996","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib44","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1572-0241.2003.07426.x","article-title":"Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors","volume":"98","author":"Graham","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1523-5378.2005.00307.x","article-title":"Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori Eradication","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jac\/39.5.585","article-title":"In-vitro activity of lansoprazole against Helicobacter pylori","volume":"39","author":"Figura","year":"1997","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.gtc.2006.03.004_bib47","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1046\/j.1365-2036.2003.01583.x","article-title":"Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication","volume":"17","author":"Graham","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3201\/eid1006.030744","article-title":"Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States","volume":"10","author":"Duck","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1523-5378.2005.00286.x","article-title":"Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003","volume":"10","author":"Watanabe","year":"2005","journal-title":"Helicobacter"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jcp.45.3.225","article-title":"Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori","volume":"45","author":"van Zanten","year":"1992","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1005457226341","article-title":"Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach","volume":"45","author":"Dore","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.1994.tb00303.x","article-title":"Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence","volume":"8","author":"Tytgat","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.gtc.2006.03.004_bib53","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1128\/AAC.44.11.3203-3205.2000","article-title":"Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori","volume":"44","author":"Kwon","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib54","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2036.1997.00172.x","article-title":"Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection","volume":"11","author":"Segura","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","article-title":"Treatment of Helicobacter pylori infection: a review of the world literature","volume":"1","author":"van der Hulst","year":"1996","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2036.1997.140316000.x","article-title":"An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively","volume":"11","author":"Miehlke","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ije\/31.1.128","article-title":"Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis","volume":"31","author":"Fischbach","year":"2002","journal-title":"Int J Epidemiol"},{"issue":"Suppl B","key":"10.1016\/j.gtc.2006.03.004_bib58","doi-asserted-by":"crossref","first-page":"36B","DOI":"10.1155\/2003\/714124","article-title":"How can the current strategies for Helicobacter pylori eradication therapy be improved?","volume":"17","author":"Ford","year":"2003","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2036.2004.02029.x","article-title":"Seven-day therapy for Helicobacter pylori in the United States","volume":"20","author":"Vakil","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib60","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2036.2000.00767.x","article-title":"The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group","volume":"14","author":"Moayyedi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.gtc.2006.03.004_bib61","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1046\/j.1365-2036.2002.01244.x","article-title":"Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy","volume":"16","author":"Della Monica","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.gtc.2006.03.004_bib62","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.gtc.2006.03.004_bib63","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.gtc.2006.03.004_bib64","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1365-2036.2003.01766.x","article-title":"Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists\u2013their efficacy with antibiotics in Helicobacter pylori eradication","volume":"18","author":"Gisbert","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.gtc.2006.03.004_bib65","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1046\/j.1365-2036.1999.00542.x","article-title":"Evaluation of treatment regimens to cure Helicobacter pylori infection\u2014a meta-analysis","volume":"13","author":"Laheij","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2036.2003.01396.x","article-title":"Risk factors for failure of Helicobacter pylori therapy:\u2013results of an individual data analysis of 2,751 patients","volume":"17","author":"Broutet","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/00365529509093298","article-title":"The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?","volume":"30","author":"de Boer","year":"1995","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2036.2000.00640.x","article-title":"Furazolidone combination therapies for Helicobacter pylori infection in the United States","volume":"14","author":"Graham","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2006.03.004_bib69","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S1590-8658(02)80172-4","article-title":"Probiotics and Helicobacter pylori eradication","volume":"34","author":"Canducci","year":"2002","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.gtc.2006.03.004_bib70","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1590-8658(03)00409-2","article-title":"Use of bovine lactoferrin for Helicobacter pylori eradication","volume":"35","author":"Di Mario","year":"2003","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/00004836-200305000-00006","article-title":"Use of lactoferrin for Helicobacter pylori eradication. Preliminary results","volume":"36","author":"Di Mario","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"10.1016\/j.gtc.2006.03.004_bib72","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.dld.2005.01.017","article-title":"Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study","volume":"37","author":"Zullo","year":"2005","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib73","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2036.2003.01395.x","article-title":"Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection","volume":"17","author":"Guttner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0016-5107(98)70223-8","article-title":"Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial","volume":"47","author":"Fujii","year":"1998","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"10.1016\/j.gtc.2006.03.004_bib75","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1523-5378.2002.00079.x","article-title":"Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori","volume":"7","author":"Gotoh","year":"2002","journal-title":"Helicobacter"},{"issue":"11","key":"10.1016\/j.gtc.2006.03.004_bib76","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/01.smj.0000182486.39913.da","article-title":"Effect of N-acetyl cysteine on Helicobacter pylori","volume":"98","author":"Gurbuz","year":"2005","journal-title":"South Med J"},{"issue":"31\u201332","key":"10.1016\/j.gtc.2006.03.004_bib77","first-page":"1391","article-title":"Omeprazole\/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine","volume":"124","author":"Zala","year":"1994","journal-title":"Schweiz Med Wochenschr"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib78","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2036.2003.01461.x","article-title":"High eradication rates of Helicobacter pylori with a new sequential treatment","volume":"17","author":"Zullo","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.gtc.2006.03.004_bib79","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/j.1365-2036.2005.02519.x","article-title":"High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study","volume":"21","author":"Zullo","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib80","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2005.09.007","article-title":"Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial","volume":"129","author":"Francavilla","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.gtc.2006.03.004_bib81","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2036.2003.01694.x","article-title":"Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy","volume":"18","author":"Hassan","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib82","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1523-5378.2000.00013.x","article-title":"Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy","volume":"5","author":"Nagahara","year":"2000","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.gtc.2006.03.004_bib83","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1523-5378.1998.08019.x","article-title":"Amoxicillin\/metronidazole\/omeprazole\/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication","volume":"3","author":"Treiber","year":"1998","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinte.162.2.153","article-title":"Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study)","volume":"162","author":"Treiber","year":"2002","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1523-5378.2001.00023.x","article-title":"High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori eradication","volume":"6","author":"Gisbert","year":"2001","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1523-5378.2001.00012.x","article-title":"In search of the Holy Grail of Helicobacter pylori remedies","volume":"6","author":"Hopkins","year":"2001","journal-title":"Helicobacter"},{"issue":"5","key":"10.1016\/j.gtc.2006.03.004_bib87","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/0016-5085(95)90689-4","article-title":"Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers","volume":"108","author":"Bayerdorffer","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2006.03.004_bib88","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1523-5378.2003.00158.x","article-title":"A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"8","author":"Miehlke","year":"2003","journal-title":"Helicobacter"},{"issue":"2","key":"10.1016\/j.gtc.2006.03.004_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2036.1997.140316000.x","article-title":"An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively","volume":"11","author":"Miehlke","year":"1997","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855306000239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T17:46:28Z","timestamp":1587318388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855306000239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0889855306000239"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2006.03.004","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}